Seeking Alpha

Seattle Genetics (SGEN +4.4%) surges after RBC's Jason Kantor boosts his 2011 and 2012 sales...

Seattle Genetics (SGEN +4.4%) surges after RBC's Jason Kantor boosts his 2011 and 2012 sales forecasts for the company's recently-approved Adcetris drug for treating lymphoma. Kantor claims an RBC survey of 100 hematologists suggests "rapid early adoption" of Adcetris.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs